Jump to content

SCLC: Lurbinectedin vs Topotecan - 2nd-line


Recommended Posts

I completed my layman's comparison of Lubinectedin vs Topotecan this morning. I compared data from the recent Lurbinectedin phase II trial and a 2015 Scientific Reports pooled systematic review of Topotecan [Scientific Reports 5:15437 DOI: 10.1038/srep15437]. In my untrained opinion, Lurbinectedin beats Topotecan easily for 2nd-line treatment! My comparison data is shown below. Please research definitions of acronyms in the NCI dictionary. Comparison order of numbers will be Lurbinectedin vs Topotecan.

OS 6mos (refractory): 61.9% to 37%

OS 1yr (refractory): 22.9% to 9%

OS 6mos (sensitive): 92.7% to 57%

OS 1yr (sensitive): 59.1% to 27%

DCR (refractory): 61% to 29%

DCR (sensitive): 79% to 42%

PR (refractory): 33.3% to 3%

PR (sensitive): 44.4% to 14%

PD (refractory): 37% to 59%

PD (sensitive): 17.6% to 48%

AE (grade 3/4): 34.3% to 69%

OS (mos): 9.3 to 5.8

PFS (mos): 3.9 to 3.9

ORR: 35.2% to 24%

Refractory vs sensitive is disease recurrence < vs > 3 months after 1st-line treatment. OS is overall survival; DCR is disease control rate; PR is partial response; PD is progressive disease; AE is adverse event; PFS is progression-free survival; and ORR is overall response rate.

An oncologist should be able to explain the comparison and whether it is valid, since the data is not "head-to-head". Let's hope the drug Lurbinectedin becomes available soon.



Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.